Founder Of Batu BiologicsExpands Involvement As Chief Scientific Officer

SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Thomas Ichim, PhD, to the position of Chief Scientific Officer. Dr. Ichim was instrumental in the founding of Batu Biologics as well as the development of the ValloVax platform, and will be taking on a larger role in the scientific advancement of the company’s therapeutic pipeline.